The discovery of PCSK9 inhibitors: A tale of creativity and multifaceted translational research

[first paragraph of article] Atherosclerosis, obesity, and metabolic syndrome are closely linked and constitute, arguably, the most menacing three conditions to modern society. Thus urgent, concerted efforts at several levels, utilising modern tools, are required to tackle them. Translational research is a rapidly expanding branch of science, dedicated to rapid delivery of discoveries from the bench to the bedside. The growing importance of this specialty in our field is evidenced by the establishment of the International Society of Cardiovascular Translational Research and its dedicated Journal by Nabil Dib and colleagues.

[1]  R. Giugliano,et al.  Efficacy and Safety of Longer-Term Administration of Evolocumab (AMG 145) in Patients With Hypercholesterolemia: 52-Week Results From the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) Randomized Trial , 2014, Circulation.

[2]  B. Bettencourt,et al.  Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial , 2014, The Lancet.

[3]  A. Sahebkar.  Beyond anti-PCSK9 therapies: the potential role of resistin inhibitors , 2014, Nature Reviews Cardiology.

[4]  Joseph L. Goldstein.  Juxtapositions in Trafalgar Square: tip-offs to creativity in art and science , 2013, Nature Medicine.

[5]  J. Kastelein,et al.  Diagnosis and treatment of familial hypercholesterolaemia. , 2013, European heart journal.

[6]  V. Gebski,et al.  Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. , 2012, JAMA.

[7]  M. Yacoub,et al.  Adipose tissue: friend or foe? , 2012, Nature Reviews Cardiology.

[8]  O. Palyha,et al.  Discovery of a new role of human resistin in hepatocyte low-density lipoprotein receptor suppression mediated in part by proprotein convertase subtilisin/kexin type 9. , 2012, Journal of the American College of Cardiology.

[9]  J. Chaparro-Riggers,et al.  Proprotein Convertase Substilisin/Kexin Type 9 Antagonism Reduces Low-Density Lipoprotein Cholesterol in Statin-Treated Hypercholesterolemic Nonhuman Primates , 2012, Journal of Pharmacology and Experimental Therapeutics.

[10]  R Bailén Almorox,et al.  [Effect of a monoclonal antibody to PCSK9 on LDL cholesterol]. , 2012, Revista clinica espanola.

[11]  M. Yacoub,et al.  Translational Lessons from a Case of Combined Heart and Liver Transplantation for Familial Hypercholesterolemia 20 Years Post-operatively , 2012, Journal of Cardiovascular Translational Research.

[12]  Lora Hamuro,et al.  A PCSK9-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces LDL cholesterol in vivo1[S] , 2011, Journal of Lipid Research.

[13]  Yan Wang,et al.  A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates , 2009, Proceedings of the National Academy of Sciences.

[14]  N. Murgolo,et al.  PCSK9 binds to multiple receptors and can be functionally inhibited by an EGF-A peptide. , 2008, Biochemical and biophysical research communications.

[15]  Robert Langer,et al.  Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates , 2008, Proceedings of the National Academy of Sciences.

[16]  E. Rimm,et al.  Plasma resistin levels and risk of myocardial infarction and ischemic stroke. , 2008, The Journal of clinical endocrinology and metabolism.

[17]  N. Dib,et al.  The path from pre-clinical research to FDA approval. , 2008, Journal of cardiovascular translational research.

[18]  Alexander Pertsemlidis,et al.  Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9 , 2005, Nature Genetics.

[19]  TP Leren,et al.  Mutations in the PCSK9 gene in Norwegian subjects with autosomal dominant hypercholesterolemia , 2004, Clinical genetics.

[20]  J. Weissenbach,et al.  Mutations in PCSK9 cause autosomal dominant hypercholesterolemia , 2003, Nature Genetics.

[21]  M. Brown,et al.  Binding and degradation of low density lipoproteins by cultured human fibroblasts. Comparison of cells from a normal subject and from a patient with homozygous familial hypercholesterolemia. , 1974, The Journal of biological chemistry.

[22]  M. Brown,et al.  Familial hypercholesterolemia: identification of a defect in the regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity associated with overproduction of cholesterol. , 1973, Proceedings of the National Academy of Sciences of the United States of America.

[23]  W. Kannel,et al.  Serum lipid fractions and risk of coronary heart disease. The Framingham study. , 1969, Minnesota medicine.

[24]  W. Kannel,et al.  RISK FACTORS IN CORONARY HEART DISEASE. AN EVALUATION OF SEVERAL SERUM LIPIDS AS PREDICTORS OF CORONARY HEART DISEASE; THE FRAMINGHAM STUDY. , 1964, Annals of internal medicine.

[25]  J. Stamler.  The problem of elevated blood cholesterol. , 1960, American journal of public health and the nation's health.